A senior official of the European Medicines Agency (EMA) said in an interview published on Tuesday that there was a link between AstraZeneca’s Kovid-19 vaccine and rare blood clots in the brain.
However, the EMA said in a statement later that a review of the vaccine was ongoing and that it was expected to announce its results on Wednesday or Thursday. A spokeswoman for AstraZeneca declined to comment.
“In my opinion, we can now say that it is clear that the vaccine is associated with a blood clot in the brain. However, we still do not know the reason for this reaction, “Marco Cavalli, chairman of the vaccination team at the EMA, told Italy’s Daily Il Masseiro.
The cavalry did not provide any evidence to support his comments.
The EMA has repeatedly stated that the benefits outweigh the risks to AstraZeneca as it is the leading cause of cerebral palsy in 9.2 million people in the European Economic Area known as cerebral venous sinus thrombosis (CVST) Goes.
The World Health Organization has also endorsed the vaccine.
AstraZeneca said earlier studies had found no high risk of clotting due to the vaccine.
Cavalry said the EMA would say in its review that there was a link but there was probably no indication this week about the age of the person who should be given the Astrazneka pill.
Some countries, including France, Germany, and the Netherlands, have suspended the use of the vaccine in minors, while investigations are ongoing.
Responding to Cavalli’s remarks, the Amsterdam-based EMA said in a statement on Tuesday: ”
The EMA said last week that its review did not identify any of the most dangerous factors at this time, such as age, gender, or previous medical history of gout. The agency said the causal link to the vaccine was not proven but was possible and further analysis was ongoing.
A higher proportion of reported cases affected young and middle-aged rats, but the EMA did not conclude that there was a particular risk of the AstraZeneca pill.
Scientists are exploring a number of possibilities that may explain the blood clots in the brain that occurred in the days and weeks after receiving the AstraZeneca vaccine in individuals.
European researchers have put forward a theory that the vaccine activates an abnormal antibody in some rare cases; Others are trying to figure out if the cases are related to birth control pills.
But many scientists say there is no conclusive evidence and it is not clear whether the AstraZeneca vaccine targets this part of the coronavirus because the cause of an issue is not shared by other vaccines.
A separate interview. In, E.M.A. Armando Genazani, a member of the Medicinal Products Committee for Human Use (CHMP), told La Stampa on a daily basis that it was “shameful” that the blood clot had been linked to the Astrazeneka vaccine.
The AstraZeneca vaccine is based on a modified chimpanzee adenovirus vector, Chaddox 1, developed at Oxford University and is one of several adenovirus-vector COVID-19 vaccines. Indicates the current injection rollout First The use of such viral vector vaccines worldwide.